RLAY News and Press, Relay Therapeutics Inc. From 11/10/21

CAMBRIDGE, Mass., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today reported third quarter 2021 finan...

CAMBRIDGE, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, plans to report third quarter 2021 fina...

Section 32 Raises $740 Million Venture Fund --Firm's Fourth Fund Maintains its Strategy of Investing in Companies at the Intersection of Technology and Healthcare; Firm Adds Nina Labatt as Chief Operating Officer and Chief Financial Officer-- PR Newswire SAN DIEGO ...

Shares of Relay Therapeutics (NASDAQ: RLAY) , a clinical-stage biopharmaceutical company, have risen about 30% since the stock's closing price last Friday. Investors are highly encouraged by interim clinical trial data that suggest the company's new approach to drug development can ...

Gainers: Hyzon Motors HYZN +5%. Avadel Pharmaceuticals (NASDAQ:AVDL) +4%. Allogene Therapeutics (NASDAQ:ALLO) +4%. Latch (NASDAQ:LTCH) +2%. Old National Bancorp (NASDAQ:ONB) +2%. Losers: Xiaobai Maimai (NASDAQ:HX) -4%. Clarus Therapeutics Holdings (NASDAQ:CRXT) -4%. Relay Thera...

CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today the pricing of an underwrit...

M&A headlines provided a key theme in Tuesday's pre-market trading. A host of private-equity firms are reportedly looking at GlaxoSmithKline's (NYSE:GSK) consumer unit. Meanwhile, Signet Jewelers (NYSE:SIG) rallied on a $490M purchase and raised guidance. In other news, Nike (NYSE:NKE) dr...

Gainers: QTRX +18.5%. PROG +3.7%. MTTR +2.6%. KC +2.5%. LFMD +2.2%. Losers: RLAY -8.9%. HX -6.2%. ACHL -3.4%. STLD -2.0%. ARRY -1.9%. For further details see: QTRX, PROG, RLAY and HX among after hours movers

CAMBRIDGE, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, announced today that it has commenced ...

Interim data suggest that RLY-4008 is a highly selective FGFR2 inhibitor that has not shown to be limited by off-target toxicities of hyperphosphatemia (FGFR1) and diarrhea (FGFR4) RLY-4008 demonstrated tumor shrinkage in all six pan-FGFR treatment-naïve FGFR2 fusion positi...